

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances in managing gastrointestinal... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/6-1689/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/6-1689" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances in managing gastrointestinal stromal tumor" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances in managing gastrointestinal stromal tumor.">
            <meta name="og:description" content="Read the latest article version by Florence Duffaud, Axel Le Cesne, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="11994">
            <meta name="article-id" content="11118">
            <meta name="dc.title" content="Recent advances in managing gastrointestinal stromal tumor">
            <meta name="dc.description" content="Constitutive activating mutations in KIT and platelet-derived growth factor receptor &alpha; ( PDGFR&alpha; ) are heavily involved in the pathobiology of gastrointestinal stromal tumors (GISTs). This disease has served as an effective &ldquo;proof-of-concept&rdquo; model for targeting gain-of-function kinase mutations in cancer. This review discusses the current standard of care in terms of pharmacotherapy in the management of localized and metastatic GISTs.">
            <meta name="dc.subject" content="gastrointestinal stromal tumours, tyrosine kinase inhibitors, microscopic complete resection">
            <meta name="dc.creator" content="Duffaud, Florence">
            <meta name="dc.creator" content="Le Cesne, Axel">
            <meta name="dc.date" content="2017/09/14">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.11118.1">
            <meta name="dc.source" content="F1000Research 2017 6:1689">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="gastrointestinal stromal tumours">
            <meta name="prism.keyword" content="tyrosine kinase inhibitors">
            <meta name="prism.keyword" content=" microscopic complete resection">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2017/09/14">
            <meta name="prism.volume" content="6">
            <meta name="prism.number" content="1689">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.11118.1">
            <meta name="prism.url" content="https://f1000research.com/articles/6-1689">
            <meta name="citation_title" content="Recent advances in managing gastrointestinal stromal tumor">
            <meta name="citation_abstract" content="Constitutive activating mutations in KIT and platelet-derived growth factor receptor &alpha; ( PDGFR&alpha; ) are heavily involved in the pathobiology of gastrointestinal stromal tumors (GISTs). This disease has served as an effective &ldquo;proof-of-concept&rdquo; model for targeting gain-of-function kinase mutations in cancer. This review discusses the current standard of care in terms of pharmacotherapy in the management of localized and metastatic GISTs.">
            <meta name="citation_description" content="Constitutive activating mutations in KIT and platelet-derived growth factor receptor &alpha; ( PDGFR&alpha; ) are heavily involved in the pathobiology of gastrointestinal stromal tumors (GISTs). This disease has served as an effective &ldquo;proof-of-concept&rdquo; model for targeting gain-of-function kinase mutations in cancer. This review discusses the current standard of care in terms of pharmacotherapy in the management of localized and metastatic GISTs.">
            <meta name="citation_keywords" content="gastrointestinal stromal tumours, tyrosine kinase inhibitors, microscopic complete resection">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Florence Duffaud">
            <meta name="citation_author_institution" content="Service d&rsquo;Oncologie M&eacute;dicale, CHU La Timone, Marseille, France">
            <meta name="citation_author_institution" content="UMR S910 INSERM, Marseille, France">
            <meta name="citation_author_institution" content="Aix-Marseille Universit&eacute;, Marseille, France">
            <meta name="citation_author" content="Axel Le Cesne">
            <meta name="citation_author_institution" content="D&eacute;partement d&rsquo;Oncologie M&eacute;dicale, Gustave Roussy Institut, Villejuif, France">
            <meta name="citation_publication_date" content="2017/09/14">
            <meta name="citation_volume" content="6">
            <meta name="citation_publication_number" content="1689">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.11118.1">
            <meta name="citation_firstpage" content="1689">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/6-1689/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/6-1689.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=11994 /> <input type=hidden id=articleId name=articleId value=11118 /> <input type=hidden id=xmlUrl value="/articles/6-1689/v1/xml"/> <input type=hidden id=xmlFileName value="-6-1689-v1.xml"> <input type=hidden id=article_uuid value=0acf35d6-7aac-4b4a-ad5f-bbcc97c8532f /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances in managing gastrointestinal stromal tumor"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.11118.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.11118.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/6-1689"
  },
  "headline": "Recent advances in managing gastrointestinal stromal tumor",
  "datePublished": "2017-09-14T14:02:11",
  "dateModified": "2017-09-14T14:02:11",
  "author": [
    {
      "@type": "Person",
      "name": "Florence Duffaud"
    },    {
      "@type": "Person",
      "name": "Axel Le Cesne"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Constitutive activating mutations in KIT and platelet-derived growth factor receptor &alpha; (PDGFR&alpha;) are heavily involved in the pathobiology of gastrointestinal stromal tumors (GISTs). This disease has served as an effective &ldquo;proof-of-concept&rdquo; model for targeting gain-of-function kinase mutations in cancer. This review discusses the current standard of care in terms of pharmacotherapy in the management of localized and metastatic GISTs."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/6-1689",
            "name": "Recent advances in managing gastrointestinal stromal tumor"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances in managing gastrointestinal stromal tumor </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=11994 data-id=11118 data-downloads="" data-views="" data-scholar="10.12688/f1000research.11118.1" data-recommended="" data-doi="10.12688/f1000research.11118.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/6-1689/v1/pdf?article_uuid=0acf35d6-7aac-4b4a-ad5f-bbcc97c8532f" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-11118-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-11118-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-11118-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Duffaud F and Le Cesne A. Recent advances in managing gastrointestinal stromal tumor [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):1689 (<a class=new-orange href="https://doi.org/10.12688/f1000research.11118.1" target=_blank>https://doi.org/10.12688/f1000research.11118.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-11118-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=11118 id=track-article-signin-11118 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/11118?target=/articles/6-1689">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=11994 /> <input name=articleId type=hidden value=11118 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances in managing gastrointestinal stromal tumor</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:florence.duffaud@ap-hm.fr" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Florence Duffaud</span></a><sup>1-3</sup>,&nbsp;</span><span class="">Axel Le Cesne<sup>4</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:florence.duffaud@ap-hm.fr" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Florence Duffaud</span></a><sup>1-3</sup>,&nbsp;</span><span class="">Axel Le Cesne<sup>4</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 14 Sep 2017 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.11118.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Service d&rsquo;Oncologie M&eacute;dicale, CHU La Timone, Marseille, France<br/> <sup>2</sup> UMR S910 INSERM, Marseille, France<br/> <sup>3</sup> Aix-Marseille Universit&eacute;, Marseille, France<br/> <sup>4</sup> D&eacute;partement d&rsquo;Oncologie M&eacute;dicale, Gustave Roussy Institut, Villejuif, France<br/> <p> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=25966-25858></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=25965-25857></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Constitutive activating mutations in <i>KIT </i>and platelet-derived growth factor receptor  (<i>PDGFR</i>) are heavily involved in the pathobiology of gastrointestinal stromal tumors (GISTs). This disease has served as an effective proof-of-concept model for targeting gain-of-function kinase mutations in cancer. This review discusses the current standard of care in terms of pharmacotherapy in the management of localized and metastatic GISTs. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> gastrointestinal stromal tumours, tyrosine kinase inhibitors, microscopic complete resection </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Florence Duffaud (<a href="mailto:florence.duffaud@ap-hm.fr">florence.duffaud@ap-hm.fr</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Florence Duffaud </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> The authors declare that they have no competing interests. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp;  2017 Duffaud F and Le Cesne A. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Duffaud F and Le Cesne A. Recent advances in managing gastrointestinal stromal tumor [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):1689 (<a href="https://doi.org/10.12688/f1000research.11118.1" target=_blank>https://doi.org/10.12688/f1000research.11118.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 14 Sep 2017, <b>6</b>(F1000 Faculty Rev):1689 (<a href="https://doi.org/10.12688/f1000research.11118.1" target=_blank>https://doi.org/10.12688/f1000research.11118.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 14 Sep 2017, <b>6</b>(F1000 Faculty Rev):1689 (<a href="https://doi.org/10.12688/f1000research.11118.1" target=_blank>https://doi.org/10.12688/f1000research.11118.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d22841e161>Introduction</h2><p class="" id=d22841e164>Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms that arise in the gastrointestinal tract. Surgery is the cornerstone of treatment for primary localized tumors which can easily be resected without inducing functional deficits. Prior to the advent of the first tyrosine kinase inhibitors (TKIs) like imatinib, there were few treatment options available to patients with advanced GIST, and their prognosis was dismal, with survival generally measured in weeks to a few months. This article presents an evaluation of current GIST management, discusses important practice points that may impact upon questions of therapy for primary and metastatic GISTs, emphasizes the most recent advances in the field, and discusses emerging steps to prevent and improve the outcomes for TKI-refractory disease.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d22841e170>Advanced and metastatic GIST management</h2><div class=section><a name=d22841e173 class=n-a></a><h3 class=section-title>Imatinib as first-line treatment for advanced/metastatic GISTs</h3><p class="" id=d22841e178>Imatinib has been considered the standard first-line therapy for inoperable or metastatic GISTs since its approval in 2002. It is an inhibitor of a few kinases including KIT, platelet-derived growth factor receptor  (PDGFRA), ABL, and CSF1R. The standard dose is 400 mg/day. A higher dosage (800 mg/day) for <i>KIT</i> exon 9-mutated GISTs was endorsed by the NCCN and ESMO guidelines<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a></sup>, as it demonstrated a significant progression-free survival (PFS) advantage (HR 0.89, 95% CI 0.791.00) despite the fact that no difference in overall survival (OS) was observed<sup><a href="#ref-3">3</a>,<a href="#ref-4">4</a></sup>. For patients treated with first-line imatinib for advanced/metastatic GIST, half to two-thirds experience an objective response after imatinib treatment, according to RECIST, with a median time to response of 34 months. Despite the important benefit in most patients, the median time to progression (TTP) is approximately 24 to 30 months<sup><a href="#ref-5">5</a><a href="#ref-7">7</a></sup>, and median OS is approximately 5760 months<sup><a href="#ref-5">5</a><a href="#ref-7">7</a></sup>. Nearly 50% of patients survive for more than 5 years, irrespective of imatinib starting dose, with approximately 1523% of patients showing a durable response lasting for more than 10 years<sup><a href="#ref-4">4</a><a href="#ref-10">10</a></sup>. Patients with stable disease lasting for more than 6 months show favorable survival outcomes comparable to those with objective responses<sup><a href="#ref-8">8</a></sup>. However, 1015% of metastatic GIST patients show intolerance or primary resistance to imatinib (defined as progressive disease within 3 months of imatinib initiation). These tumors most commonly are those with mutations in <i>PDGFRA</i>, particularly the D842V mutation in exon 18, or those lacking mutations in either <i>KIT</i> or <i>PDGFRA</i>.</p></div><div class=section><a name=d22841e234 class=n-a></a><h3 class=section-title>Does the type of mutation affect prognosis in metastatic GISTs?</h3><p class="" id=d22841e239>Multiple trials have confirmed the superior prognosis of patients with advanced GISTs who have a <i>KIT</i> exon 11 mutation and are treated with imatinib, compared with other mutation subtypes<sup><a href="#ref-6">6</a>,<a href="#ref-10">10</a>,<a href="#ref-11">11</a></sup>. Upon analysis of the period of response in the common mutation subgroups, exon 11 mutations demonstrated the longest PFS, and exon 9 mutations or patients lacking both <i>KIT</i> and <i>PDGFRA</i>, i.e. the variant which once was called wild-type mutations, exhibited less favorable PFS<sup><a href="#ref-4">4</a>,<a href="#ref-11">11</a>,<a href="#ref-12">12</a></sup>. Since the majority of wild-type GISTs are now identified as having genetic or epigenetic loss of succinate dehydrogenase (SDH) subunits, the more accurate term is generally SDH-deficient GIST, unless there is some other rare mutation such as <i>BRAF V600E, NF1</i> deletions, or <i>NTRK</i> fusions. OS was also different in those with a <i>KIT</i> exon 11 mutation compared to those with exon 9 mutated or wild-type GIST, but no significant difference in OS has been reported between exon 9 mutated and wild-type GIST patients. Complete responses to TKI therapy are very rare.</p><p class="" id=d22841e281>A large proportion of patients with advanced GISTs in whom imatinib is useful demonstrate persistent measurable disease and ultimately develop progressive disease, usually within 23 years. The most common mechanism of resistance to TKIs in patients with GISTs occurs because of clonal evolution. These clones express the primary mutation along with additional mutations that render them resistant to imatinib, leading to treatment failure and progression of disease (most often in pre-existing sites of bulk disease); the secondary resistance mutations occur in the same gene that was originally activated by mutation. The most common secondary mutations occur in two regions of the KIT protein: the ATP-binding pocket (encoded by exons 13 and 14) and the kinase activation loop (encoded by exons 17 and 18)<sup><a href="#ref-13">13</a><a href="#ref-15">15</a></sup>.</p></div><div class=section><a name=d22841e292 class=n-a></a><h3 class=section-title>For how long should imatinib treatment be continued?</h3><p class="" id=d22841e297>The French BFR14 trial addressed the question of imatinib dosing interruption in metastatic GISTs following initial disease controls after 1, 3, and 5 years of daily treatment with 400 mg of imatinib in non-progressive patients who have not yet developed progressive disease. In patients randomized to stop imatinib dosing, the median PFS after initial disease control of 1, 3, or 5 years was quite short (only 7, 9, or 13 months, respectively); in comparison, the patients randomized to continue imatinib dosing continued to maintain disease control with a median PFS of 29 months for the group randomized after the first year of disease control, and median PFS was much longer and not reached at the time of the report in patients randomized after 3 or 5 years of disease control<sup><a href="#ref-16">16</a><a href="#ref-18">18</a></sup>. Although the majority of patients who progressed after dosing interruption were able to regain control of the progressive disease, a small number of patients had continuation of progression, and this led to the standard of care to avoid lengthy dosing interruptions of imatinib in patients with disease stability or response. The worldwide standard is that imatinib should optimally be continued in metastatic GIST until disease progression, even for patients who may have obtained a complete response via radical excision of residual GIST masses during imatinib treatment.</p><p class="" id=d22841e307>The French BFR14 study also asked what the effect of long-term continuous imatinib therapy was on the evolution of secondary resistance<sup><a href="#ref-18">18</a></sup>. The endpoint of time to secondary resistance (TSR) was defined as the time to disease progression while on imatinib dosing. The 2-year PFS following randomization (in the continuous treatment arm) increased from 62% (in the patients randomized after 1 year of initial disease control) to 80% (for those patients randomized after 3 years of disease control<sup><a href="#ref-19">19</a></sup>). Of course, the evolution of secondary resistance is a function of the individuals disease biology as well as the length of continuous control of imatinib. These results demonstrate that the rate of secondary resistance decreases over time, suggesting the possibility of long-term tumor control with continuous imatinib in a significant subset of patients with metastatic GISTs. These results were also reported in the most recent update from the long-term results of the B2222 phase II trial<sup><a href="#ref-20">20</a></sup>.</p></div><div class=section><a name=d22841e323 class=n-a></a><h3 class=section-title>What is the appropriate therapy with evidence of disease progression on imatinib?</h3><p class="" id=d22841e328><b><i>Prolongation of imatinib therapy by dose escalation.</i></b> Three randomized trials performed early in the clinical development of imatinib for GIST have demonstrated a benefit with a higher dose of imatinib in patients progressing on 400 mg per day. Clinical results from the EORTC and SWOG studies<sup><a href="#ref-3">3</a>,<a href="#ref-5">5</a>,<a href="#ref-21">21</a></sup>, in which patients were allowed to crossover to higher-dose imatinib (800 mg/day) after initial progression, revealed that disease was controlled for some period of time in approximately one-third of patients after dose escalation. The median PFS following progression and crossover to a higher dose of imatinib was 3 and 5 months in the EORTC and SWOG trials, respectively<sup><a href="#ref-3">3</a>,<a href="#ref-5">5</a>,<a href="#ref-21">21</a></sup>. A meta-analysis of these combined results indicated that the benefit from such dose escalation was virtually all in the subset of patients whose GIST harbored <i>KIT</i> exon 9 mutations<sup><a href="#ref-11">11</a></sup>. Additionally, long-term data in the B2222 phase II trial demonstrated that approximately 25% of patients progressing on a low dose benefited from a dose increase<sup><a href="#ref-6">6</a>,<a href="#ref-20">20</a></sup>. Consequently, a dose increase to 400 mg twice daily is an option when imatinib resistance develops, especially for patients with a low plasma imatinib concentration<sup><a href="#ref-22">22</a>,<a href="#ref-23">23</a></sup>.</p></div><div class=section><a name=d22841e378 class=n-a></a><h3 class=section-title>Sunitinib: second-line treatment in patients with GIST after failure or intolerance to imatinib</h3><p class="" id=d22841e383>Since the failure of imatinib, sunitinib malate (Sutent), a multi-target TKI with powerful activity against <i>KIT and PDGFRA</i>, as well as a number of other kinases, has demonstrated efficacy as a second-line therapy and is now approved globally for use in metastatic GIST in patients who are resistant or intolerant to imatinib based on the results of a double-blind, placebo-controlled phase III trial<sup><a href="#ref-24">24</a></sup>. In this study, 312 patients were enrolled and randomized to receive sunitinib or placebo. Sunitinib dose was 50 mg daily administered on a schedule of 4 weeks on and 2 weeks off. Despite a very low objective response rate (7%) in the sunitinib arm, the median PFS rates were 6.3 and 1.5 months in the sunitinib and placebo arms, respectively (HR 0.33, <i>p</i>&lt;0.0001). The primary end-point, TTP, was fourfold higher in the sunitinib arm compared with placebo (27 versus 6 weeks, respectively). Despite crossover, OS was better, even though it was not significant, in the sunitinib arm than in the placebo arm (HR 0.49). The most frequent treatment-related adverse events were fatigue, diarrhea, hand-foot syndrome, and hypothyroidism<sup><a href="#ref-24">24</a></sup>.</p><p class="" id=d22841e400>In addition, a phase II single arm looked at the feasibility of a daily dosing of sunitinib at a continuous dose of 37.5 mg<sup><a href="#ref-23">23</a></sup>. The clinical benefit rate was 53%, with a median PFS of 34 weeks and a median OS of 107 weeks, and the toxicity profile was similar to that seen in the phase III study. The continuous use of 37.5 mg daily was later approved in the US and EU and is considered an alternative dosing schedule<sup><a href="#ref-25">25</a></sup>. Similar to the mechanisms of acquired secondary resistance with imatinib, resistance to sunitinib can be explained in large part by the development of other secondary mutations in <i>KIT</i> which allow the kinase to escape the inhibitory action of sunitinib. The assessments of tumor genotype following imatinib failure can predict the sensitivity of resistance to sunitinib, to a great extent. The degree of disease control, including length of PFS and median OS, was noted to be significantly higher in patients whose GIST was characterized by a primary exon 9 mutation in <i>KIT</i> or those with no mutations in either <i>KIT</i> or <i>PDGFRA.</i> Secondary mutations were also correlated with activity of sunitinib with sensitivity in the gatekeeper mutations in the <i>KIT</i> ATP-binding pocket, whereas mutations in the exon 17 <i>KIT</i> region encoding the kinase activation loop were generally resistant to sunitinib as well as imatinib<sup><a href="#ref-26">26</a></sup>.</p></div><div class=section><a name=d22841e435 class=n-a></a><h3 class=section-title>Regorafenib: a recent standard of care for metastatic GISTs</h3><p class="" id=d22841e440>Regorafenib is an oral TKI that inhibits numerous kinases that participate in oncogenesis (KIT, PDGFRA, RET, RAF1, and BRAF V600E), angiogenesis (VEGFR13 and TIE2), and the tumor microenvironment (PDGFR and FGFR)<sup><a href="#ref-27">27</a></sup>. In a phase II trial that included 33 patients with GISTs resistant to imatinib and sunitinib but who were sorafenib naive, regorafenib at a dose of 160 mg daily for 3 weeks, in a 4-week cycle, showed a clinical benefit rate of 79% (95% CI 6191%) and a median PFS of 10 months<sup><a href="#ref-28">28</a></sup>. Long-term follow-up (FU) results of this phase II trial, with a median FU of 41 months, reported a median PFS of 13.2 months (95% CI 9.218.3 months) and a median OS of 25 months (95% CI 13.239.1 months) and showed that patients whose tumors harbored a <i>KIT</i> exon 11 mutation demonstrated the longest median PFS (13.4 months), whereas patients with <i>KIT/PDGFRA</i> wild-type and non-SDH complex (non-SDH)-deficient tumors experienced a median PFS of 1.6 months (<i>p</i>&lt;0.0001)<sup><a href="#ref-29">29</a></sup>.</p><p class="" id=d22841e465>Based on these promising results, a randomized (2:1), double-blind, placebo-controlled phase III study<sup><a href="#ref-30">30</a></sup> was performed in patients with GISTs resistant to both imatinib and sunitinib; the primary end-point was PFS. A total of 199 patients were allocated to regorafenib 160 mg/day or placebo (3 weeks on and 1 week off) until disease progression, along with best supportive care in both arms. Patients were unblinded at the time of disease progression; however, those on placebo were able to crossover to the study drug if permitted by the investigator<sup><a href="#ref-30">30</a></sup>. The results of this trial favored regorafenib, with median PFS of 4.8 months for patients initially randomized to regorafenib compared with 0.9 months for those randomized initially to the placebo arm (HR 0.27, 95% CI 0.190.39, <i>p</i>&lt;0.0001). Given the rapidity of the disease progression and the fact that the majority of patients on placebo were able to crossover to regorafenib on unblinding, it is not surprising that no difference in OS was observed between the two study arms. The clinical benefit of regorafenib was studied in sensitivity testing and found to be consistent across all prospectively identified subsets of patients, except for the very small subset of patients with primary resistance to imatinib (defined as those whose initial duration of imatinib treatment was &lt;6 months). Regorafenib-related adverse events grade III or higher were reported in 61% of patients, and the most common were hypertension and hand-foot skin reaction. A total of 58% of patients required dose interruption and 50% required dose reductions for adverse events, but there was little occurrence of treatment discontinuation<sup><a href="#ref-30">30</a></sup>. Based on these results, regorafenib was approved as a third-line standard of care in metastatic GISTs after failure or intolerance to imatinib and sunitinib.</p></div><div class=section><a name=d22841e484 class=n-a></a><h3 class=section-title>Imatinib rechallenge as an alternative strategy after failure of imatinib and sunitinib</h3><p class="" id=d22841e489>Despite the remarkable advances in the therapeutic options for metastatic GISTs, the overwhelming majority of patients will develop resistance to all available TKI therapies and exhibit refractory disease progression despite all TKIs. Re-introduction of imatinib dosing has been a common practice despite prior failure, justified by evidence that rapidly symptomatic disease progression can be a nearly universal occurrence if all TKI therapy is discontinued. There is evidence that some bulky subsets of tumor cells are controlled by any TKI therapy and that the withdrawal of all TKI suppression allows the entirety of tumor clones to expand rapidly. A randomized, double-blind, placebo-controlled, phase III trial known as RIGHT was performed in Korea to formally assess the potential benefits of imatinib resumption in patients with imatinib-refractory GISTs following progression after at least imatinib and sunitinib, with the caveat that they must demonstrate prior initial benefit from imatinib in the first-line setting<sup><a href="#ref-31">31</a></sup>. Following disease progression, a total of 81 patients were randomized to receive either imatinib 400 mg daily or matching placebo. Imatinib was well tolerated, and median PFS with imatinib was twice that for patients receiving placebo (1.8 versus 0.9 months, respectively), together with a disease control rate at 12 weeks of 32%. There was no notable improvement in OS. Thus, the benefit seen with the rechallenge of imatinib in TKI-refractory GIST has been suggested to be caused by the constant kinase inhibition of the majority of disease clones that have no acquired mutations; however, the short PFS indicates that resistant clones still grow. The advantages of imatinib rechallenge offset its toxicities, reinforcing its clinical significance for patients without active treatment options available to minimize symptom-worsening GISTs, especially since quality of life was not impaired by imatinib in this fragile population<sup><a href="#ref-32">32</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d22841e504>Role of surgery in metastatic GIST</h2><p class="" id=d22841e507>Most patients reach partial response or stable disease on imatinib, but around half acquire secondary resistance after 2 years. Existing data indicate that cytoreductive surgery could be a possibility in imatinib-responsive patients with metastatic GISTs, especially if there is successful complete (R0/R1) resection of residual metastatic disease<sup><a href="#ref-1">1</a>,<a href="#ref-33">33</a><a href="#ref-37">37</a></sup>. The value of surgery in patients with focal tumor progression being treated with imatinib is uncertain, but this approach is a possible option. Recently, the role of cytoreductive surgery for metastatic GISTs treated with TKIs was reported in a two-institution large analysis after 400 operations were performed on 323 patients<sup><a href="#ref-35">35</a></sup>. The authors concluded that surgery in metastatic GIST patients in the absence of multifocal progressive disease on imatinib is associated with outcomes that are at least comparable with second-line sunitinib and may be considered in selected patients<sup><a href="#ref-35">35</a></sup>.</p><p class="" id=d22841e528>Overall, patients with multifocal progression undergoing surgery have a poor result. Surgery does not seem to benefit patients with generalized disease progression on imatinib<sup><a href="#ref-37">37</a></sup> and should not be offered unless as an emergency where palliative intervention may be justified<sup><a href="#ref-35">35</a></sup>. Although surgery is a viable option for metastatic GIST patients treated with sunitinib, it is common for incomplete resections to occur, there is a high chance of complications, and there is uncertainty regarding the survival benefit<sup><a href="#ref-33">33</a></sup>. Clinicians must adopt a considered multidisciplinary consultation to establish the best local treatment choices in metastatic GIST patients, on an individual basis, after sharing the decision with the patient<sup><a href="#ref-33">33</a></sup>.</p><div class=section><a name=d22841e547 class=n-a></a><h3 class=section-title>Localized GISTs</h3><p class="" id=d22841e552>Microscopic complete resection with histologically negative margins (R0) without rupturing the tumor is the standard treatment for localized GISTs<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a>,<a href="#ref-38">38</a></sup>. Although a significant proportion of patients will be cured with surgery alone, approximately 40% will eventually relapse, the great majority within the first 5 years<sup><a href="#ref-38">38</a><a href="#ref-40">40</a></sup>. These outcomes underscore the need for adjuvant therapy. Given the efficacy of imatinib in the metastatic setting, the use of imatinib has been extended to the adjuvant setting for the treatment of adult patients following GIST resection<sup><a href="#ref-41">41</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d22841e580>Risk factors associated with GIST recurrence</h2><p class="" id=d22841e583>Independent prognostic factors for GIST include tumor size and site, mitotic count, and tumor rupture<sup><a href="#ref-40">40</a></sup>. Risk stratification is essential to identify and better define the patients with GIST who are most likely to benefit from adjuvant imatinib therapy<sup><a href="#ref-42">42</a>,<a href="#ref-43">43</a></sup>. Among the risk-stratification schemes currently available for operable GISTs, the most widely used are the National Institutes of Health (NIH) consensus classification<sup><a href="#ref-44">44</a></sup>, Armed Forces Institute of Pathology (AFIP) criteria<sup><a href="#ref-45">45</a></sup>, and the modified NIH classification<sup><a href="#ref-42">42</a></sup>. These three classifications were recently found to have roughly similar prognostic accuracy in a series of 2,560 patients with resected GISTs who never received adjuvant imatinib<sup><a href="#ref-39">39</a></sup>. Notably, regardless of the classification scheme used, patients identified as intermediate risk had a clinical course similar to that of the low-risk group.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d22841e617>Does adjuvant imatinib prolong recurrence-free survival or OS compared to placebo?</h2><p class="" id=d22841e620>Three randomized phase III clinical trials (see <a href="#T1">Table 1</a>) have examined the use of imatinib 400 mg daily as an adjuvant for 1, 2, and 3 years<sup><a href="#ref-46">46</a><a href="#ref-48">48</a></sup>; all three showed that it extends recurrence-free survival (RFS) in comparison with placebo or surveillance.</p><div class="table-wrap panel clearfix"><a name=T1 class=n-a></a><div class=caption><h3>Table 1. Phase III clinical trials of adjuvant imatinib therapy.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d22841e644 class=n-a></a><tbody><a name=d22841e646 class=n-a></a><tr><a name=d22841e648 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d22841e650 class=n-a></a>Duration</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22841e653 class=n-a></a>3 years of adjuvant IM</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22841e656 class=n-a></a>2 years of adjuvant IM</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22841e659 class=n-a></a>1 year of adjuvant IM</td></tr><tr><a name=d22841e663 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d22841e665 class=n-a></a>Trial</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22841e668 class=n-a></a>SSGXVIII/AIO</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22841e671 class=n-a></a>EORTC 62024</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22841e674 class=n-a></a>ACOZOG Z9001</td></tr><tr><a name=d22841e678 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d22841e680 class=n-a></a>IM dosage</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22841e683 class=n-a></a>400 mg/day for 1 versus 3 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22841e686 class=n-a></a>400 mg/day for 2 years versus<br class=br>control (no IM)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22841e691 class=n-a></a>400mg/day for 1 year versus control<br class=br>(no IM)</td></tr><tr><a name=d22841e697 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d22841e699 class=n-a></a>IM duration</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22841e702 class=n-a></a>MFU=54 months</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22841e705 class=n-a></a>MFU=4.7 years</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22841e708 class=n-a></a>MFU=19.7 months</td></tr><tr><a name=d22841e712 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d22841e714 class=n-a></a>Patients</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22841e717 class=n-a></a>n=400<br class=br>Resected GIST (R0) with high risk<br class=br>of recurrence</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22841e724 class=n-a></a>N=908<br class=br>KIT-positive completely resected<br class=br>GIST with intermediate or high risk<br class=br>of recurrence</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22841e733 class=n-a></a>KIT-positive after complete resection,<br class=br>T &gt;3 cm, with low, intermediate, or high<br class=br>risk of recurrence</td></tr><tr><a name=d22841e742 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d22841e744 class=n-a></a>Primary end-point</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22841e747 class=n-a></a>RFS</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22841e750 class=n-a></a>Time to secondary resistance</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22841e753 class=n-a></a>RFS</td></tr><tr><a name=d22841e757 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d22841e759 class=n-a></a>Efficacy results</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22841e762 class=n-a></a>RFS at 5 years: 65.6% (3 years)<br class=br>versus 47.9% (1 year) (<i>p</i>&lt;0001)<br class=br>OS at 5 years: 92% (3 years)<br class=br>versus 81.7% (1 year) (p&lt;0.02) 2d<br class=br>analysis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22841e776 class=n-a></a>RFS at 3 years: 84% (2 years)<br class=br>versus 66% (control)<br class=br>OS at 5 years: 100% (2 years)<br class=br>versus 99% (control)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d22841e785 class=n-a></a>98% for IM versus 83% for placebo<br class=br>HR 0.35, <i>p</i>&lt;0.0001<br class=br>No significant difference in 1-year OS</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=note-1 class=n-a></a><p id=d22841e802> GIST, gastrointestinal stromal tumor; HR, hazard ratio; IM, imatinib; MFU, median follow-up; OS, overall survival; RFS, recurrence-free survival</p></div></div></div><p class="" id=d22841e808>Additionally, the initial and long-term results provided by the AIO study<sup><a href="#ref-47">47</a>,<a href="#ref-49">49</a></sup> demonstrated that 3 years of imatinib significantly improves RFS and OS compared with 1 year of therapy.</p><p class="" id=d22841e818>According to survival findings in the AIO trial, 3 years of adjuvant imatinib therapy are recommended for patients with GIST with high-risk features. To investigate whether the survival benefits have persisted, the authors performed the second planned analysis of the trial<sup><a href="#ref-49">49</a></sup>. In this second analysis<sup><a href="#ref-49">49</a></sup>, with a median FU of 90 months, patients randomized to 3-year imatinib dosing had longer disease control than those assigned to the 1-year dosing group; the relapse-free survival (RFS) rate after 5 years was 71% versus 52%, respectively (HR 0.60; 95% CI 0.440.81; <i>p</i>&lt;0.001), and OS was also significantly improved: 92% versus 85% (HR 0.60; 95% CI 0.370.97; <i>p</i>=0.036)<sup><a href="#ref-49">49</a></sup>.</p><p class="" id=d22841e840>Despite the AIO trial survival findings, the optimal duration of adjuvant therapy remains unknown and is still being investigated. There is one non-randomized phase II trial of 5 years of adjuvant imatinib treatment that enrolled 91 high-risk GIST patients and showed that chronic imatinib was effective in preventing recurrences during treatment for patients with sensitive mutations; it also demonstrated 5-year RFS and OS rates of 90% and 95%, respectively, but 49% of patients discontinued treatment early<sup><a href="#ref-50">50</a></sup>. Moreover, two randomized trials are ongoing in high-risk GIST patients: a Scandinavian study comparing 5 years<sup><a href="#ref-51">51</a></sup> with 3 years and a French study comparing 6 years<sup><a href="#ref-52">52</a></sup> to 3 years of imatinib.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d22841e859>Do all patients benefit from adjuvant imatinib?</h2><p class="" id=d22841e862>A study that retrospectively analyzed Z9001 trial data proposed that high-risk patients derived greater efficacy from adjuvant therapy (tumor size &gt;10 cm and high mitotic rate)<sup><a href="#ref-46">46</a></sup>. The use of adjuvant imatinib is not recommended for low risk and very low risk, but there is no consensus for intermediate risk<sup><a href="#ref-53">53</a></sup>. In this situation, the risks and benefits of treatment should be shared with the patient. A randomized phase II trial is ongoing in France (GIGIST study) comparing imatinib over 3 years versus surveillance in intermediate-risk patients with a high-risk genomic grade index<sup><a href="#ref-54">54</a></sup>.</p><p class="" id=d22841e877>Recent data from the Z9001 trial shed light on the efficacy of imatinib in different mutational subtypes<sup><a href="#ref-55">55</a></sup>. Imatinib was superior to placebo in prolonging RFS only in patients with deletions in <i>KIT</i> exon 11. It did not delay recurrence compared to placebo in <i>KIT</i> exon 11 point mutations or insertions, exon 9 mutations, or wild-type GIST<sup><a href="#ref-55">55</a></sup>. Imatinib was not statistically superior to placebo in <i>PDGFRA</i>-mutant tumors; however, the sample size was small. Similar data have been reported in the AIO trial examining the effect of 1 versus 3 years of imatinib<sup><a href="#ref-47">47</a></sup>. A meta-analysis of the three phase III randomized studies would be useful and instructive to have a better idea of the genotypes that benefit most or least from imatinib as adjuvant.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d22841e905>Does adjuvant imatinib affect the development of imatinib resistance?</h2><p class="" id=d22841e908>Results from the EORTC phase III trial<sup><a href="#ref-48">48</a></sup> examining 2 years of adjuvant imatinib compared to surveillance, with a median FU of 4.7 years, reported that the time to initiation of a different TKI following recurrence (i.e. imatinib failure-free survival, IFFS), a surrogate for secondary resistance, was equivalent in both treatments arms (5-year IFFS was 87% in the imatinib arm versus 84% in the control arm; HR 0.79; <i>p</i>=0.21)<sup><a href="#ref-41">41</a></sup>. RFS was 84% versus 66% at 3 years and 69% versus 63% at 5 years (log rank <i>p</i>&lt;0.01). The AIO trial also demonstrated no difference in time to progression following salvage imatinib in patients initially treated with either 1 or 3 years of adjuvant imatinib<sup><a href="#ref-47">47</a></sup>, suggesting that there is no evidence that the duration of prior adjuvant therapy has an impact on the TSR in the advanced setting.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d22841e932>Imatinib in the neoadjuvant setting</h2><p class="" id=d22841e935>Imatinib demonstrates high response rates in patients with metastatic GIST; therefore, the purpose of its preoperative use is in tumor bulk reduction in order to ease complete surgical resection or make organ preservation more likely in initially unresectable or borderline resectable disease. In the absence of phase III trials, the role of neoadjuvant imatinib therapy remains investigational, but data from retrospective series and a few prospective phase II trials have demonstrated the efficacy and safety of neoadjuvant imatinib in locally advanced GISTs<sup><a href="#ref-56">56</a><a href="#ref-58">58</a></sup>. Patient selection and duration of therapy are currently at the discretion of the medical oncologist and surgeon. NCCN and ESMO guidelines<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a></sup> recommend neoadjuvant imatinib in patients who have primary, unresectable tumors or resectable tumors with a risk of significant morbidity but with an early tumor response assessment so that surgery is not delayed in case of non-responding disease. An initial dose of 400 mg daily is indicated; however, patients with exon 9 mutations may benefit from dose escalation. Imatinib should be continued for 69 months but not extended beyond 12 months because of the risk of imatinib resistance and of usually minor additional tumor shrinkage<sup><a href="#ref-56">56</a>,<a href="#ref-59">59</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d22841e962>Recent advances: new promising drugs</h2><p class="" id=d22841e965>In the last 10 years or so, research has yielded the discovery and greater understanding of the biological mechanisms behind GIST survival and proliferation. Only recently, a more comprehensive molecular analysis has shown that <i>KIT/PDGFRA</i> wild-type GIST is a rather heterogeneous group of different diseases rather than one single entity<sup><a href="#ref-60">60</a></sup>.</p><p class="" id=d22841e975>Between 20 and 40% of all <i>KIT/PDGFRA</i> wild-type GISTs are SDH-deficient, as recognized by the loss of SDH subunit B (SDHB) protein expression, which is most often due to germline and/or somatic loss-of-function mutations in any of the four SDH subunits (A, B, C, or D)<sup><a href="#ref-61">61</a>,<a href="#ref-62">62</a></sup>. These tumors are designated as SDH-deficient GISTs or SDHB-negative GISTs<sup><a href="#ref-63">63</a></sup>. The most common subtype of SDH-deficient GIST is made up of tumors with SDHA mutations<sup><a href="#ref-63">63</a></sup>.</p><p class="" id=d22841e996>The subgroup of the remaining <i>KIT/PDGFRA</i> wild-type, but not SDH-deficient, GISTs have been further characterized: about 15% possess an activating mutation in <i>BRAF</i> or, more infrequently, a <i>RAS</i> gene<sup><a href="#ref-64">64</a></sup>. Furthermore, wild-type GISTs may appear in the setting of syndromic neurofibromatosis type I (NF1) disease, in which there is a loss of function of the NF1 protein<sup><a href="#ref-65">65</a></sup>. Together, GISTs with mutations in <i>BRAF/RAS</i> or NF1 are known as RAS pathway (RAS-P) mutant GISTs. Approximately 5% of all GISTs lack functionally relevant mutations in <i>KIT PDGFR, BRAF</i>, or NF1 without deficient SDH complexes (as shown by maintaining expression of SDHB by immunohistochemistry); the oncogenic drivers of quadruple negative GIST remain uncertain and possibly more complex than other larger classes of GIST<sup><a href="#ref-60">60</a>,<a href="#ref-63">63</a></sup>. Some of these may be explained by newly identified oncogenic fusions in NTRK.</p><p class="" id=d22841e1030>These last 15 years have led to the approval of three drugs (imatinib, sunitinib, and regorafenib) for the treatment of advanced GISTs, which have significantly improved survival. However, nearly all patients with metastatic GISTs will become resistant to those therapies. Various new targeted therapies are under evaluation in clinical trials for imatinib-resistant GISTs, with major interest in new promising multi-kinase inhibitors such as ponatinib, BLU-285, and crenolanib.</p><p class="" id=d22841e1034>Ponatinib, a next-generation TKI approved in imatinib-resistant BCR-ABL leukemia, has shown activity in engineered and GIST-derived cell lines, potently inhibits <i>KIT</i> exon 11 primary mutants and a range of secondary mutants, including those within the A-loop, and has been shown to induce regression in engineered and GIST-derived tumor models containing these secondary mutations<sup><a href="#ref-66">66</a></sup>. The preliminary results from a non-randomized phase II trial that evaluated ponatinib at a dose of 45 mg/day in heavily treated GIST patients (74% had four or more prior agents) demonstrated a clinical benefit rate (CR, PR, or SD  16 weeks) of 55% in patients with primary <i>KIT</i> exon 11 mutation, but responses were also observed with the 30 mg dose<sup><a href="#ref-67">67</a></sup>.</p><p class="" id=d22841e1051>More recently, BLU-285, a new investigational agent, has shown highly potent and selective targeting of <i>KIT/PDGFRA</i> GIST mutants and high activity against imatinib-resistant GIST patient-derived xenografts of a <i>KIT</i> exon 11/17 mutant and a <i>KIT</i> exon 11/13 mutant<sup><a href="#ref-68">68</a></sup>. BLU-285 is a mutation-specific inhibitor of kinases with mutations in <i>KIT</i> D816V and <i>PDGFRA</i> D842V, in which most TKIs are ineffective. It appears to have favorable toxicity, as indicated by preclinical data, but we await the results of clinical trials<sup><a href="#ref-69">69</a></sup>. The results of the dose escalation part of a phase I study were recently presented at the 2017 ASCO meeting<sup><a href="#ref-70">70</a></sup> and showed that BLU-285 is well tolerated on a QD schedule at doses up to the MTD of 400 mg and that its exposure at 300400 mg QD provides broad coverage of primary and secondary <i>KIT/PDGFRA</i> mutants. BLU-285 has strong clinical activity in <i>PDGFRA</i> D842-mutant GISTs with an ORR of 60% per central review, and median PFS was not reached. It also demonstrates important anti-tumor activity including radiographic response and prolonged PFS in heavily pre-treated, <i>KIT</i>-mutant GISTs at doses of 300400 mg QD<sup><a href="#ref-70">70</a></sup>. Based on these encouraging data, planning is underway for a phase III randomized study of BLU-285 in third-line metastatic GISTs.</p><p class="" id=d22841e1096>The oral small-molecule inhibitor crenolanib exhibits activity against FLT3 and the PDGFRs (including D842V-mutated kinase)<sup><a href="#ref-71">71</a></sup>. Metastatic <i>PDGFRA</i>-mutant GIST is exceptionally unusual, and a phase II trial with seven patients demonstrated objective response in one and SD in three<sup><a href="#ref-72">72</a></sup>. A randomized, double-blind, placebo-controlled, multicenter, phase III trial of crenolanib in subjects with advanced or metastatic GIST with D842V mutation in the <i>PDGFRA</i> gene is ongoing<sup><a href="#ref-73">73</a></sup>.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d22841e1 class=n-a></a><h2 class=main-title id=d23084>Competing interests</h2><p class=metadata-entry><a name=d22841e96 class=n-a></a><p id=d22841e98> The authors declare that they have no competing interests.</p></p></div><div class=back-section><a name=d22841e1 class=n-a></a><h2 class=main-title id=d23086>Grant information</h2><p>The author(s) declared that no grants were involved in supporting this work.</p></div><div class=back-section><a name=d22841e1121 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d23312>References</h2><div class="section ref-list"><a name=d22841e1121 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d22841e1128 class=n-a></a>ESMO/European Sarcoma Network Working Group: Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol.</i> 2014; <b>25 Suppl 3</b>:iii216. <a target=xrefwindow id=d22841e1136 href="http://www.ncbi.nlm.nih.gov/pubmed/25210085">PubMed Abstract </a> | <a target=xrefwindow id=d22841e1139 href="http://dx.doi.org/10.1093/annonc/mdu255">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d22841e1148 class=n-a></a>von Mehren M, Randall RL, Benjamin RS, <i> et al.</i>: Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. <i>J Natl Compr Canc Netw.</i> 2016; <b>14</b>(6): 75886. <a target=xrefwindow id=d22841e1159 href="http://www.ncbi.nlm.nih.gov/pubmed/27283169">PubMed Abstract </a> | <a target=xrefwindow id=d22841e1162 href="http://dx.doi.org/10.6004/jnccn.2016.0078 ">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d22841e1171 class=n-a></a>Verweij J, Casali PG, Zalcberg J, <i> et al.</i>: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. <i>Lancet.</i> 2004; <b>364</b>(9440): 112734. <a target=xrefwindow id=d22841e1182 href="http://www.ncbi.nlm.nih.gov/pubmed/15451219">PubMed Abstract </a> | <a target=xrefwindow id=d22841e1185 href="http://dx.doi.org/10.1016/S0140-6736(04)17098-0">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/2281958"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22841e1194 class=n-a></a>Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST): Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. <i>J Clin Oncol.</i> 2010; <b>28</b>(7): 124753. <a target=xrefwindow id=d22841e1202 href="http://www.ncbi.nlm.nih.gov/pubmed/20124181">PubMed Abstract </a> | <a target=xrefwindow id=d22841e1205 href="http://dx.doi.org/10.1200/JCO.2009.24.2099">Publisher Full Text </a> | <a target=xrefwindow id=d22841e1208 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2834472">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/2281958">F1000 Recommendation</a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d22841e1221 class=n-a></a>Blanke CD, Rankin C, Demetri GD, <i> et al.</i>: Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. <i>J Clin Oncol.</i> 2008; <b>26</b>(4): 62632. <a target=xrefwindow id=d22841e1232 href="http://www.ncbi.nlm.nih.gov/pubmed/18235122">PubMed Abstract </a> | <a target=xrefwindow id=d22841e1235 href="http://dx.doi.org/10.1200/JCO.2007.13.4452">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d22841e1245 class=n-a></a>Blanke CD, Demetri GD, von Mehren M, <i> et al.</i>: Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing <i>KIT</i>. <i>J Clin Oncol.</i> 2008; <b>26</b>(4): 6205. <a target=xrefwindow id=d22841e1259 href="http://www.ncbi.nlm.nih.gov/pubmed/18235121">PubMed Abstract </a> | <a target=xrefwindow id=d22841e1263 href="http://dx.doi.org/10.1200/JCO.2007.13.4403">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d22841e1272 class=n-a></a>Patrikidou A, Domont J, Chabaud S, <i> et al.</i>: Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR<sub>14</sub> trial of the French Sarcoma Group. <i>Eur J Cancer.</i> 2016; <b>52</b>: 17380. <a target=xrefwindow id=d22841e1286 href="http://www.ncbi.nlm.nih.gov/pubmed/26687836">PubMed Abstract </a> | <a target=xrefwindow id=d22841e1290 href="http://dx.doi.org/10.1016/j.ejca.2015.10.069">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d22841e1299 class=n-a></a>Le Cesne A, van Glabbeke M, Verweij J, <i> et al.</i>: Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. <i>J Clin Oncol.</i> 2009; <b>27</b>(24): 396974. <a target=xrefwindow id=d22841e1310 href="http://www.ncbi.nlm.nih.gov/pubmed/19620483">PubMed Abstract </a> | <a target=xrefwindow id=d22841e1313 href="http://dx.doi.org/10.1200/JCO.2008.21.3330">Publisher Full Text </a> | <a target=xrefwindow id=d22841e1317 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2799153">Free Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d22841e1326 class=n-a></a>Demetri GD, von Mehren M, Blanke CD, <i> et al.</i>: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. <i>N Engl J Med.</i> 2002; <b>347</b>: 47280. <a target=xrefwindow id=d22841e1337 href="http://www.ncbi.nlm.nih.gov/pubmed/12181401">PubMed Abstract </a> | <a target=xrefwindow id=d22841e1340 href="http://dx.doi.org/10.1056/NEJMoa020461">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d22841e1349 class=n-a></a>Heinrich MC, Rankin C, Blanke CD, <i> et al.</i>: Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. <i>JAMA Oncol</i> 2017; <b>3</b>(7): 944952. <a target=xrefwindow id=d22841e1360 href="http://www.ncbi.nlm.nih.gov/pubmed/28196207">PubMed Abstract </a> | <a target=xrefwindow id=d22841e1363 href="http://dx.doi.org/10.1001/jamaoncol.2016.6728">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d22841e1372 class=n-a></a>Debiec-Rychter M, Sciot R, Le Cesne A, <i> et al.</i>: <i>KIT</i> mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. <i>Eur J Cancer.</i> 2006; <b>42</b>(8): 1093103. <a target=xrefwindow id=d22841e1386 href="http://www.ncbi.nlm.nih.gov/pubmed/16624552">PubMed Abstract </a> | <a target=xrefwindow id=d22841e1390 href="http://dx.doi.org/10.1016/j.ejca.2006.01.030">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d22841e1400 class=n-a></a>Heinrich MC, Owzar K, Corless CL, <i> et al.</i>: Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. <i>J Clin Oncol.</i> 2008; <b>26</b>(33): 53607. <a target=xrefwindow id=d22841e1411 href="http://www.ncbi.nlm.nih.gov/pubmed/18955451">PubMed Abstract </a> | <a target=xrefwindow id=d22841e1414 href="http://dx.doi.org/10.1200/JCO.2008.17.4284">Publisher Full Text </a> | <a target=xrefwindow id=d22841e1418 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2651078">Free Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d22841e1427 class=n-a></a>Antonescu CR, Besmer P, Guo T, <i> et al.</i>: Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. <i>Clin Cancer Res.</i> 2005; <b>11</b>(11): 418290. <a target=xrefwindow id=d22841e1438 href="http://www.ncbi.nlm.nih.gov/pubmed/15930355">PubMed Abstract </a> | <a target=xrefwindow id=d22841e1441 href="http://dx.doi.org/10.1158/1078-0432.CCR-04-2245">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d22841e1450 class=n-a></a>Debiec-Rychter M, Cools J, Dumez H, <i> et al.</i>: Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. <i>Gastroenterology.</i> 2005; <b>128</b>(2): 2709. <a target=xrefwindow id=d22841e1461 href="http://www.ncbi.nlm.nih.gov/pubmed/15685537">PubMed Abstract </a> | <a target=xrefwindow id=d22841e1464 href="http://dx.doi.org/10.1053/j.gastro.2004.11.020">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d22841e1473 class=n-a></a>Heinrich MC, Corless CL, Blanke CD, <i> et al.</i>: Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. <i>J Clin Oncol.</i> 2006; <b>24</b>(29): 476474. <a target=xrefwindow id=d22841e1484 href="http://www.ncbi.nlm.nih.gov/pubmed/16954519">PubMed Abstract </a> | <a target=xrefwindow id=d22841e1487 href="http://dx.doi.org/10.1200/JCO.2006.06.2265">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d22841e1496 class=n-a></a>Blay JY, Le Cesne A, Ray-Coquard I, <i> et al.</i>: Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. <i>J Clin Oncol.</i> 2007; <b>25</b>(9): 110713. <a target=xrefwindow id=d22841e1507 href="http://www.ncbi.nlm.nih.gov/pubmed/17369574">PubMed Abstract </a> | <a target=xrefwindow id=d22841e1510 href="http://dx.doi.org/10.1200/JCO.2006.09.0183">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d22841e1519 class=n-a></a>Le Cesne A, Ray-Coquard I, Bui BN, <i> et al.</i>: Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. <i>Lancet Oncol.</i> 2010; <b>11</b>(10): 9429. <a target=xrefwindow id=d22841e1530 href="http://www.ncbi.nlm.nih.gov/pubmed/20864406">PubMed Abstract </a> | <a target=xrefwindow id=d22841e1533 href="http://dx.doi.org/10.1016/S1470-2045(10)70222-9">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d22841e1543 class=n-a></a>Le Cesne A, Ray-Coquard IL, Bui Nguyen B, <i> et al.</i>: Time to secondary resistance (TSR) after interruption of imatinib (IM) in advanced GIST: Updated results of the prospective French Sarcoma Group randomized phase III trial on long-term survival. <i>JCO.</i> 2011; <b>29</b>: 10015. <a target=xrefwindow id=d22841e1554 href="http://dx.doi.org/10.1200/jco.2011.29.15_suppl.10015">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d22841e1563 class=n-a></a>Ray-Coquard IL, Bin Bui N, Adenis A, <i> et al.</i>: Risk of relapse with imatinib (IM) discontinuation at 5 years in advanced GIST patients: Results of the prospective BFR14 randomized phase III study comparing interruption versus continuation of IM at 5 years of treatment: A French Sarcoma Group Study. <i>JCO.</i> 2010; <b>28</b>: 10032. <a target=xrefwindow id=d22841e1574 href="http://dx.doi.org/10.1200/jco.2010.28.15_suppl.10032">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d22841e1583 class=n-a></a>von Mehren M, Heinrich MC, Joensuu H, <i> et al.</i>: Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST). <i>JCO.</i> 2011; <b>29</b>: 10016. <a target=xrefwindow id=d22841e1594 href="http://dx.doi.org/10.1200/jco.2011.29.15_suppl.10016">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d22841e1603 class=n-a></a>Zalcberg JR, Verweij J, Casali PG, <i> et al.</i>: Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. <i>Eur J Cancer.</i> 2005; <b>41</b>(12): 17517. <a target=xrefwindow id=d22841e1614 href="http://www.ncbi.nlm.nih.gov/pubmed/16098458">PubMed Abstract </a> | <a target=xrefwindow id=d22841e1617 href="http://dx.doi.org/10.1016/j.ejca.2005.04.034">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d22841e1626 class=n-a></a>Bouchet S, Poulette S, Titier K, <i> et al.</i>: Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting. <i>Eur J Cancer.</i> 2016; <b>57</b>: 318. <a target=xrefwindow id=d22841e1637 href="http://www.ncbi.nlm.nih.gov/pubmed/26851399">PubMed Abstract </a> | <a target=xrefwindow id=d22841e1640 href="http://dx.doi.org/10.1016/j.ejca.2015.12.029">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d22841e1649 class=n-a></a>Demetri GD, Wang Y, Wehrle E, <i> et al.</i>: Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. <i>J Clin Oncol.</i> 2009; <b>27</b>(19): 31417. <a target=xrefwindow id=d22841e1660 href="http://www.ncbi.nlm.nih.gov/pubmed/19451435">PubMed Abstract </a> | <a target=xrefwindow id=d22841e1663 href="http://dx.doi.org/10.1200/JCO.2008.20.4818">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/719898971"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22841e1673 class=n-a></a>Demetri GD, van Oosterom AT, Garrett CR, <i> et al.</i>: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. <i>Lancet.</i> 2006; <b>368</b>(9544): 132938. <a target=xrefwindow id=d22841e1684 href="http://www.ncbi.nlm.nih.gov/pubmed/17046465">PubMed Abstract </a> | <a target=xrefwindow id=d22841e1687 href="http://dx.doi.org/10.1016/S0140-6736(06)69446-4">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/719898971">F1000 Recommendation</a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d22841e1700 class=n-a></a>George S, Blay JY, Casali PG, <i> et al.</i>: Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. <i>Eur J Cancer.</i> 2009; <b>45</b>(11): 195968. <a target=xrefwindow id=d22841e1711 href="http://www.ncbi.nlm.nih.gov/pubmed/19282169">PubMed Abstract </a> | <a target=xrefwindow id=d22841e1714 href="http://dx.doi.org/10.1016/j.ejca.2009.02.011">Publisher Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1157329"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22841e1723 class=n-a></a>Heinrich MC, Maki RG, Corless CL, <i> et al.</i>: Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. <i>J Clin Oncol.</i> 2008; <b>26</b>(33): 53529. <a target=xrefwindow id=d22841e1734 href="http://www.ncbi.nlm.nih.gov/pubmed/18955458">PubMed Abstract </a> | <a target=xrefwindow id=d22841e1737 href="http://dx.doi.org/10.1200/JCO.2007.15.7461">Publisher Full Text </a> | <a target=xrefwindow id=d22841e1741 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2651076">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1157329">F1000 Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d22841e1754 class=n-a></a>Wilhelm SM, Dumas J, Adnane L, <i> et al.</i>: Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. <i>Int J Cancer.</i> 2011; <b>129</b>(1): 24555. <a target=xrefwindow id=d22841e1765 href="http://www.ncbi.nlm.nih.gov/pubmed/21170960">PubMed Abstract </a> | <a target=xrefwindow id=d22841e1768 href="http://dx.doi.org/10.1002/ijc.25864">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717697922"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22841e1777 class=n-a></a>George S, Wang Q, Heinrich MC, <i> et al.</i>: Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. <i>J Clin Oncol.</i> 2012; <b>30</b>(19): 24017. <a target=xrefwindow id=d22841e1788 href="http://www.ncbi.nlm.nih.gov/pubmed/22614970">PubMed Abstract </a> | <a target=xrefwindow id=d22841e1791 href="http://dx.doi.org/10.1200/JCO.2011.39.9394">Publisher Full Text </a> | <a target=xrefwindow id=d22841e1795 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3675695">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717697922">F1000 Recommendation</a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726479284"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22841e1808 class=n-a></a>Ben-Ami E, Barysauskas CM, von Mehren M, <i> et al.</i>: Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. <i>Ann Oncol.</i> 2016; <b>27</b>(9): 17949. <a target=xrefwindow id=d22841e1819 href="http://www.ncbi.nlm.nih.gov/pubmed/27371698">PubMed Abstract </a> | <a target=xrefwindow id=d22841e1822 href="http://dx.doi.org/10.1093/annonc/mdw228">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726479284">F1000 Recommendation</a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717967428"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22841e1836 class=n-a></a>Demetri GD, Reichardt P, Kang YK, <i> et al.</i>: Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. <i>Lancet.</i> 2013; <b>381</b>(9863): 295302. <a target=xrefwindow id=d22841e1847 href="http://www.ncbi.nlm.nih.gov/pubmed/23177515">PubMed Abstract </a> | <a target=xrefwindow id=d22841e1850 href="http://dx.doi.org/10.1016/S0140-6736(12)61857-1">Publisher Full Text </a> | <a target=xrefwindow id=d22841e1854 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3819942">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717967428">F1000 Recommendation</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718149040"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22841e1867 class=n-a></a>Kang YK, Ryu MH, Yoo C, <i> et al.</i>: Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncol.</i> 2013; <b>14</b>(12): 117582. <a target=xrefwindow id=d22841e1878 href="http://www.ncbi.nlm.nih.gov/pubmed/24140183">PubMed Abstract </a> | <a target=xrefwindow id=d22841e1881 href="http://dx.doi.org/10.1016/S1470-2045(13)70453-4">Publisher Full Text </a> | <a target=xrefwindow id=d22841e1885 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4347867">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718149040">F1000 Recommendation</a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726037796"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22841e1898 class=n-a></a>Yoo C, Ryu MH, Nam BH, <i> et al.</i>: Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT). <i>Eur J Cancer.</i> 2016; <b>52</b>: 2018. <a target=xrefwindow id=d22841e1909 href="http://www.ncbi.nlm.nih.gov/pubmed/26699729">PubMed Abstract </a> | <a target=xrefwindow id=d22841e1912 href="http://dx.doi.org/10.1016/j.ejca.2015.10.071">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726037796">F1000 Recommendation</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d22841e1925 class=n-a></a>Keung EZ, Fairweather M, Raut CP: The Role of Surgery in Metastatic Gastrointestinal Stromal Tumors. <i>Curr Treat Options Oncol.</i> 2016; <b>17</b>(2): 8. <a target=xrefwindow id=d22841e1933 href="http://www.ncbi.nlm.nih.gov/pubmed/26820287">PubMed Abstract </a> | <a target=xrefwindow id=d22841e1936 href="http://dx.doi.org/10.1007/s11864-015-0384-y">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d22841e1945 class=n-a></a>Bauer S, Rutkowski P, Hohenberger P, <i> et al.</i>: Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study). <i>Eur J Surg Oncol.</i> 2014; <b>40</b>(4): 4129. <a target=xrefwindow id=d22841e1956 href="http://www.ncbi.nlm.nih.gov/pubmed/24491288">PubMed Abstract </a> | <a target=xrefwindow id=d22841e1959 href="http://dx.doi.org/10.1016/j.ejso.2013.12.020">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d22841e1968 class=n-a></a>Fairweather M, Balachandran VP, Li GZ, <i> et al.</i>: Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated With Tyrosine Kinase Inhibitors: A 2-institutional Analysis. <i>Ann Surg.</i> 2017. <a target=xrefwindow id=d22841e1976 href="http://www.ncbi.nlm.nih.gov/pubmed/28448384">PubMed Abstract </a> | <a target=xrefwindow id=d22841e1979 href="http://dx.doi.org/10.1097/SLA.0000000000002281">Publisher Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d22841e1989 class=n-a></a>Bamboat ZM, DeMatteo RP: Metastasectomy for gastrointestinal stromal tumors. <i>J Surg Oncol.</i> 2014; <b>109</b>(1): 237. <a target=xrefwindow id=d22841e1997 href="http://www.ncbi.nlm.nih.gov/pubmed/24155153">PubMed Abstract </a> | <a target=xrefwindow id=d22841e2000 href="http://dx.doi.org/10.1002/jso.23451">Publisher Full Text </a> | <a target=xrefwindow id=d22841e2003 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4086871">Free Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d22841e2012 class=n-a></a>Ford SJ, Gronchi A: Indications for surgery in advanced/metastatic GIST. <i>Eur J Cancer.</i> 2016; <b>63</b>: 15467. <a target=xrefwindow id=d22841e2020 href="http://www.ncbi.nlm.nih.gov/pubmed/27318456">PubMed Abstract </a> | <a target=xrefwindow id=d22841e2023 href="http://dx.doi.org/10.1016/j.ejca.2016.05.019">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d22841e2032 class=n-a></a>DeMatteo RP, Lewis JJ, Leung D, <i> et al.</i>: Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. <i>Ann Surg.</i> 2000; <b>231</b>(1): 518. <a target=xrefwindow id=d22841e2043 href="http://www.ncbi.nlm.nih.gov/pubmed/10636102">PubMed Abstract </a> | <a target=xrefwindow id=d22841e2046 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1420965">Free Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d22841e2055 class=n-a></a>Joensuu H, Vehtari A, Riihimki J, <i> et al.</i>: Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. <i>Lancet Oncol.</i> 2012; <b>13</b>(3): 26574. <a target=xrefwindow id=d22841e2066 href="http://www.ncbi.nlm.nih.gov/pubmed/22153892">PubMed Abstract </a> | <a target=xrefwindow id=d22841e2069 href="http://dx.doi.org/10.1016/S1470-2045(11)70299-6">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d22841e2078 class=n-a></a>Gold JS, Gnen M, Gutirrez A, <i> et al.</i>: Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. <i>Lancet Oncol.</i> 2009; <b>10</b>(11): 104552. <a target=xrefwindow id=d22841e2089 href="http://www.ncbi.nlm.nih.gov/pubmed/19793678">PubMed Abstract </a> | <a target=xrefwindow id=d22841e2092 href="http://dx.doi.org/10.1016/S1470-2045(09)70242-6">Publisher Full Text </a> | <a target=xrefwindow id=d22841e2096 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3175638">Free Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d22841e2105 class=n-a></a>Cohen MH, Cortazar P, Justice R, <i> et al.</i>: Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumors. <i>Oncologist.</i> 2010; <b>15</b>(3): 3007. <a target=xrefwindow id=d22841e2116 href="http://www.ncbi.nlm.nih.gov/pubmed/20200041">PubMed Abstract </a> | <a target=xrefwindow id=d22841e2119 href="http://dx.doi.org/10.1634/theoncologist.2009-0120">Publisher Full Text </a> | <a target=xrefwindow id=d22841e2123 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3227955">Free Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d22841e2133 class=n-a></a>Joensuu H: Risk stratification of patients diagnosed with gastrointestinal stromal tumor. <i>Hum Pathol.</i> 2008; <b>39</b>(10): 14119. <a target=xrefwindow id=d22841e2141 href="http://www.ncbi.nlm.nih.gov/pubmed/18774375">PubMed Abstract </a> | <a target=xrefwindow id=d22841e2144 href="http://dx.doi.org/10.1016/j.humpath.2008.06.025">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d22841e2153 class=n-a></a>Rutkowski P, Bylina E, Wozniak A, <i> et al.</i>: Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes. <i>Eur J Surg Oncol.</i> 2011; <b>37</b>(10): 8906. <a target=xrefwindow id=d22841e2164 href="http://www.ncbi.nlm.nih.gov/pubmed/21737227">PubMed Abstract </a> | <a target=xrefwindow id=d22841e2167 href="http://dx.doi.org/10.1016/j.ejso.2011.06.005">Publisher Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d22841e2176 class=n-a></a>Fletcher CD, Berman JJ, Corless C, <i> et al.</i>: Diagnosis of gastrointestinal stromal tumors: A consensus approach. <i>Hum Pathol.</i> 2002; <b>33</b>(5): 45965. <a target=xrefwindow id=d22841e2187 href="http://www.ncbi.nlm.nih.gov/pubmed/12094370">PubMed Abstract </a> | <a target=xrefwindow id=d22841e2190 href="http://dx.doi.org/10.1053/hupa.2002.123545">Publisher Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d22841e2199 class=n-a></a>Miettinen M, Lasota J: Gastrointestinal stromal tumors: pathology and prognosis at different sites. <i>Semin Diagn Pathol.</i> 2006; <b>23</b>(2): 7083. <a target=xrefwindow id=d22841e2207 href="http://www.ncbi.nlm.nih.gov/pubmed/17193820">PubMed Abstract </a> | <a target=xrefwindow id=d22841e2210 href="http://dx.doi.org/10.1053/j.semdp.2006.09.001">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1157706"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22841e2219 class=n-a></a>Dematteo RP, Ballman KV, Antonescu CR, <i> et al.</i>: Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. <i>Lancet.</i> 2009; <b>373</b>(9669): 1097104. <a target=xrefwindow id=d22841e2230 href="http://www.ncbi.nlm.nih.gov/pubmed/19303137">PubMed Abstract </a> | <a target=xrefwindow id=d22841e2233 href="http://dx.doi.org/10.1016/S0140-6736(09)60500-6">Publisher Full Text </a> | <a target=xrefwindow id=d22841e2237 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2915459">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1157706">F1000 Recommendation</a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/716497827"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22841e2250 class=n-a></a>Joensuu H, Eriksson M, Sundby Hall K, <i> et al.</i>: One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. <i>JAMA.</i> 2012; <b>307</b>(12): 126572. <a target=xrefwindow id=d22841e2261 href="http://www.ncbi.nlm.nih.gov/pubmed/22453568">PubMed Abstract </a> | <a target=xrefwindow id=d22841e2264 href="http://dx.doi.org/10.1001/jama.2012.347">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/716497827">F1000 Recommendation</a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d22841e2278 class=n-a></a>Casali PG, Le Cesne A, Poveda Velasco A, <i> et al.</i>: Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. <i>J Clin Oncol.</i> 2015; <b>33</b>(36): 427683. <a target=xrefwindow id=d22841e2289 href="http://www.ncbi.nlm.nih.gov/pubmed/26573069">PubMed Abstract </a> | <a target=xrefwindow id=d22841e2292 href="http://dx.doi.org/10.1200/JCO.2015.62.4304">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725906529"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22841e2301 class=n-a></a>Joensuu H, Eriksson M, Sundby Hall K, <i> et al.</i>: Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial. <i>J Clin Oncol.</i> 2016; <b>34</b>(3): 24450. <a target=xrefwindow id=d22841e2312 href="http://www.ncbi.nlm.nih.gov/pubmed/26527782">PubMed Abstract </a> | <a target=xrefwindow id=d22841e2315 href="http://dx.doi.org/10.1200/JCO.2015.62.9170">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725906529">F1000 Recommendation</a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d22841e2328 class=n-a></a>Raut CP, Espat NJ, Maki RG, <i> et al.</i>: PERSIST-5: Five Year Extended Treatment with Adjuvant Imatinib for Patients with Intermediate/High Risk Primary Gastrointestinal Stromal Tumor (GIST) <i>J Clin Oncol.</i> 2017; <b>35</b>(15_suppl): (Abstract 11009). <a target=xrefwindow id=d22841e2339 href="http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.11009">Reference Source</a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d22841e2348 class=n-a></a>ClinicalTrials.gov Identifier: NCT02413736: Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST. <a target=xrefwindow id=d22841e2350 href="https://clinicaltrials.gov/ct2/show/results/NCT02413736">Reference Source</a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d22841e2359 class=n-a></a>Clinical Trials identifier: NCT02260505: Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (ImadGist). <a target=xrefwindow id=d22841e2361 href="https://clinicaltrials.gov/ct2/show/NCT02260505">Reference Source</a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d22841e2370 class=n-a></a>Nishida T, Blay JY, Hirota S, <i> et al.</i>: The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines. <i>Gastric Cancer.</i> 2016; <b>19</b>(1): 314. <a target=xrefwindow id=d22841e2381 href="http://www.ncbi.nlm.nih.gov/pubmed/26276366">PubMed Abstract </a> | <a target=xrefwindow id=d22841e2384 href="http://dx.doi.org/10.1007/s10120-015-0526-8">Publisher Full Text </a> | <a target=xrefwindow id=d22841e2388 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4688306">Free Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d22841e2398 class=n-a></a>Clinical Trials identifier: NCT 02576080: Efficacy of Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade Index (GIGIST). <a target=xrefwindow id=d22841e2400 href="https://clinicaltrials.gov/ct2/show/NCT02576080">Reference Source</a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718312257"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22841e2409 class=n-a></a>Corless CL, Ballman KV, Antonescu CR, <i> et al.</i>: Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. <i>J Clin Oncol.</i> 2014; <b>32</b>(15): 156370. <a target=xrefwindow id=d22841e2420 href="http://www.ncbi.nlm.nih.gov/pubmed/24638003">PubMed Abstract </a> | <a target=xrefwindow id=d22841e2423 href="http://dx.doi.org/10.1200/JCO.2013.51.2046">Publisher Full Text </a> | <a target=xrefwindow id=d22841e2427 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4026579">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718312257">F1000 Recommendation</a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d22841e2440 class=n-a></a>McAuliffe JC, Hunt KK, Lazar AJ, <i> et al.</i>: A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. <i>Ann Surg Oncol.</i> 2009; <b>16</b>(4): 9109. <a target=xrefwindow id=d22841e2451 href="http://www.ncbi.nlm.nih.gov/pubmed/18953611">PubMed Abstract </a> | <a target=xrefwindow id=d22841e2454 href="http://dx.doi.org/10.1245/s10434-008-0177-7">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1147293"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a> <a name=d22841e2463 class=n-a></a>Eisenberg BL, Harris J, Blanke CD, <i> et al.</i>: Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. <i>J Surg Oncol.</i> 2009; <b>99</b>(1): 427. <a target=xrefwindow id=d22841e2474 href="http://www.ncbi.nlm.nih.gov/pubmed/18942073">PubMed Abstract </a> | <a target=xrefwindow id=d22841e2477 href="http://dx.doi.org/10.1002/jso.21160">Publisher Full Text </a> | <a target=xrefwindow id=d22841e2481 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2606912">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1147293">F1000 Recommendation</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d22841e2495 class=n-a></a>Rutkowski P, Gronchi A, Hohenberger P, <i> et al.</i>: Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience. <i>Ann Surg Oncol.</i> 2013; <b>20</b>(9): 293743. <a target=xrefwindow id=d22841e2506 href="http://www.ncbi.nlm.nih.gov/pubmed/23760587">PubMed Abstract </a> | <a target=xrefwindow id=d22841e2509 href="http://dx.doi.org/10.1245/s10434-013-3013-7">Publisher Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d22841e2518 class=n-a></a>Bednarski BK, Araujo DM, Yi M, <i> et al.</i>: Analysis of prognostic factors impacting oncologic outcomes after neoadjuvant tyrosine kinase inhibitor therapy for gastrointestinal stromal tumors. <i>Ann Surg Oncol.</i> 2014; <b>21</b>(8): 2499505. <a target=xrefwindow id=d22841e2529 href="http://www.ncbi.nlm.nih.gov/pubmed/24639192">PubMed Abstract </a> | <a target=xrefwindow id=d22841e2532 href="http://dx.doi.org/10.1245/s10434-014-3632-7">Publisher Full Text </a> | <a target=xrefwindow id=d22841e2536 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4524653">Free Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d22841e2546 class=n-a></a>Nannini M, Biasco G, Astolfi A, <i> et al.</i>: An overview on molecular biology of KIT/PDGFRA wild type (WT) gastrointestinal stromal tumours (GIST). <i>J Med Genet.</i> 2013; <b>50</b>(10): 65361. <a target=xrefwindow id=d22841e2557 href="http://www.ncbi.nlm.nih.gov/pubmed/23833252">PubMed Abstract </a> | <a target=xrefwindow id=d22841e2560 href="http://dx.doi.org/10.1136/jmedgenet-2013-101695">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/8554956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22841e2569 class=n-a></a>Janeway KA, Kim SY, Lodish M, <i> et al.</i>: Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking <i>KIT</i> and <i>PDGFRA</i> mutations. <i>Proc Natl Acad Sci U S A.</i> 2011; <b>108</b>(1): 3148. <a target=xrefwindow id=d22841e2587 href="http://www.ncbi.nlm.nih.gov/pubmed/21173220">PubMed Abstract </a> | <a target=xrefwindow id=d22841e2590 href="http://dx.doi.org/10.1073/pnas.1009199108">Publisher Full Text </a> | <a target=xrefwindow id=d22841e2593 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3017134">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/8554956">F1000 Recommendation</a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d22841e2606 class=n-a></a>Pantaleo MA, Astolfi A, Indio V, <i> et al.</i>: <i>SDHA</i> loss-of-function mutations in <i>KIT</i>-<i>PDGFRA</i> wild-type gastrointestinal stromal tumors identified by massively parallel sequencing. <i>J Natl Cancer Inst.</i> 2011; <b>103</b>(12): 9837. <a target=xrefwindow id=d22841e2627 href="http://www.ncbi.nlm.nih.gov/pubmed/21505157">PubMed Abstract </a> | <a target=xrefwindow id=d22841e2630 href="http://dx.doi.org/10.1093/jnci/djr130">Publisher Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718548997"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22841e2639 class=n-a></a>Pantaleo MA, Nannini M, Corless CL, <i> et al.</i>: Q<i>uadruple</i> wild-type (WT) GIST: defining the subset of GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling pathways. <i>Cancer Med.</i> 2015; <b>4</b>(1): 1013. <a target=xrefwindow id=d22841e2653 href="http://www.ncbi.nlm.nih.gov/pubmed/25165019">PubMed Abstract </a> | <a target=xrefwindow id=d22841e2657 href="http://dx.doi.org/10.1002/cam4.325">Publisher Full Text </a> | <a target=xrefwindow id=d22841e2660 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4312123">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718548997">F1000 Recommendation</a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d22841e2673 class=n-a></a>Daniels M, Lurkin I, Pauli R, <i> et al.</i>: Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST). <i>Cancer Lett.</i> 2011; <b>312</b>(1): 4354. <a target=xrefwindow id=d22841e2684 href="http://www.ncbi.nlm.nih.gov/pubmed/21906875">PubMed Abstract </a> | <a target=xrefwindow id=d22841e2687 href="http://dx.doi.org/10.1016/j.canlet.2011.07.029">Publisher Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d22841e2696 class=n-a></a>Bajor J: Gastrointestinal stromal tumours in patients with type 1 neurofibromatosis. <i>Clin Exp Med J.</i> 2009; <b>3</b>(2): 24754. <a target=xrefwindow id=d22841e2704 href="http://dx.doi.org/10.1556/CEMED.3.2009.28478">Publisher Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718883330"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d22841e2714 class=n-a></a>Garner AP, Gozgit JM, Anjum R, <i> et al.</i>: Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. <i>Clin Cancer Res.</i> 2014; <b>20</b>(22): 574555. <a target=xrefwindow id=d22841e2725 href="http://www.ncbi.nlm.nih.gov/pubmed/25239608">PubMed Abstract </a> | <a target=xrefwindow id=d22841e2728 href="http://dx.doi.org/10.1158/1078-0432.CCR-14-1397">Publisher Full Text </a> | <a target=xrefwindow id=d22841e2732 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4233175">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718883330">F1000 Recommendation</a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d22841e2745 class=n-a></a>Heinrich MC, Von Mehren M, Demetri GD, <i> et al.</i>: A phase 2 study of ponatinib in patients with advanced gastrointestinal stromal tumors (GIST) after failure of tyrosine kinase inhibitor (TKI) therapy: initial report. <i>J Clin Oncol.</i> 2014; <b>32</b>(15S): 669s (abstract #10506). <a target=xrefwindow id=d22841e2756 href="http://ascopubs.org/doi/abs/10.1200/jco.2014.32.15_suppl.10506">Reference Source</a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d22841e2765 class=n-a></a>BLU-285, DCC-2618 Show Activity against GIST. <i>Cancer Discov.</i> 2017; <b>7</b>(2): 1212. <a target=xrefwindow id=d22841e2773 href="http://www.ncbi.nlm.nih.gov/pubmed/28077435">PubMed Abstract </a> | <a target=xrefwindow id=d22841e2776 href="http://dx.doi.org/10.1158/2159-8290.CD-NB2016-165">Publisher Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d22841e2785 class=n-a></a>Evans EK, Hodous BL, Gardino A, <i> et al.</i>: First selective KIT D816V inhibitor for patients with systemic mastocytosis. <i>Blood.</i> 2014; <b>124</b>(21): 3217. <a target=xrefwindow id=d22841e2796 href="http://www.bloodjournal.org/content/124/21/3217">Reference Source</a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d22841e2805 class=n-a></a>Heinrich M, Jones R, von Mehren M, <i> et al.</i>: Clinical activity of BLU-285 in advanced gastrointestinal stromal tumor (GIST). <i>J Clin Oncol.</i> ASCO meeting 2017; oral presentation, Abstr 11011. <a target=xrefwindow id=d22841e2813 href="http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.11011">Reference Source</a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d22841e2822 class=n-a></a>Heinrich MC, Griffith D, McKinley A, <i> et al.</i>: Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. <i>Clin Cancer Res.</i> 2012; <b>18</b>(16): 437584. <a target=xrefwindow id=d22841e2833 href="http://www.ncbi.nlm.nih.gov/pubmed/22745105">PubMed Abstract </a> | <a target=xrefwindow id=d22841e2836 href="http://dx.doi.org/10.1158/1078-0432.CCR-12-0625">Publisher Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d22841e2846 class=n-a></a>Matro JM, Yu JQ, Heinrich MC, <i> et al.</i>: Correlation of PET/CT and CT RECIST response in GIST patient with PDGFRA D842V gene mutations treated with crenolanib. <i>J Clin Oncol.</i> 2014; <b>32</b>(15S): 679s (abstract #1054). <a target=xrefwindow id=d22841e2857 href="http://ascopubs.org/doi/abs/10.1200/jco.2014.32.15_suppl.10546">Reference Source</a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d22841e2866 class=n-a></a>ClinicalTrials.govidentifier: NCT01243346): A randomized, double-blind, placebo-controlled, multicenter, phase III trial of Crenolanib in subjects with advanced or metastatic GIST with D842V mutation in the PDGFRa gene is ongoing.</span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 14 Sep 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-1689&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-1689&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Service d&rsquo;Oncologie M&eacute;dicale, CHU La Timone, Marseille, France<br/> <sup>2</sup> UMR S910 INSERM, Marseille, France<br/> <sup>3</sup> Aix-Marseille Universit&eacute;, Marseille, France<br/> <sup>4</sup> D&eacute;partement d&rsquo;Oncologie M&eacute;dicale, Gustave Roussy Institut, Villejuif, France<br/> <p> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/6-1689/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 14 Sep 2017, 6:1689 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.11118.1">https://doi.org/10.12688/f1000research.11118.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden">  2017 Duffaud F and Le Cesne A. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=11994 data-id=11118 data-downloads="" data-views="" data-scholar="10.12688/f1000research.11118.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/6-1689/v1/pdf?article_uuid=0acf35d6-7aac-4b4a-ad5f-bbcc97c8532f" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.11118.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Duffaud F and Le Cesne A. Recent advances in managing gastrointestinal stromal tumor [version 1; peer review: 2 approved] <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):1689 (<a href="https://doi.org/10.12688/f1000research.11118.1" target=_blank>https://doi.org/10.12688/f1000research.11118.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=11118 id=mobile-track-article-signin-11118 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/11118?target=/articles/6-1689"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=11994 /> <input name=articleId type=hidden value=11118 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Piotr Rutkowski</strong>, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Poland </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Ian Judson</strong>, The Institute of Cancer Research, UK </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> Professor Ian Judson has received honoraria from the following companies in the last 2 years: GSK, Lilly, Ariad & Amgen. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 14 Sep 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-1689&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-1689&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=25966-25858></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=25965-25857></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/6-1689/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>14 Sep 17</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Piotr Rutkowski</strong>, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Poland </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Ian Judson</strong>, The Institute of Cancer Research, UK </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> Professor Ian Judson has received honoraria from the following companies in the last 2 years: GSK, Lilly, Ariad & Amgen. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/6-1689&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/6-1689/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances in managing gastrointestinal...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/6-1689/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/6-1689/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/6-1689/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Duffaud F and Le Cesne A');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/6-1689/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/6-1689",
            templates : {
                twitter : "Recent advances in managing gastrointestinal stromal tumor. Duffaud F and Le Cesne A, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/6-1689/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances in managing gastrointestinal stromal tumor", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances in managing gastrointestinal stromal tumor", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/11118/11994")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "11994");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "25857": 0,
                           "25858": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "7b090c12-f2c7-4347-baec-5312515b7354";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-1689.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-1689.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-1689.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/6-1689.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/6-1689.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>